These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32520141)

  • 1. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
    Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
    J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
    [No Abstract]   [Full Text] [Related]  

  • 3. Advanced non-small cell lung cancer - Treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 5. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
    Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
    Khalife N; Kordahi M; Felefly T; Saleh K
    Future Oncol; 2021 Jul; 17(20):2559-2562. PubMed ID: 34047193
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
    Li F; Dong X
    Thorac Cancer; 2021 Dec; 12(23):3085-3087. PubMed ID: 34643064
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
    Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
    Liao W; Huang J; Hutton D; Li Q
    J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
    Qin Q; Li B
    J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
    Goldberg SB; Herbst RS
    Cancer; 2018 Dec; 124(24):4592-4596. PubMed ID: 30383887
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
    Han Z; Liu L; Jiang Y
    J Thorac Oncol; 2024 Sep; 19(9):e31-e32. PubMed ID: 39242141
    [No Abstract]   [Full Text] [Related]  

  • 16. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case of post-progression prolongation of survival after cessation of pembrolizumab in advanced non-small-cell lung cancer.
    Liu J; Wong K; Patanjali N; Boyer M; Kao S
    Intern Med J; 2020 Jun; 50(6):771-773. PubMed ID: 32537926
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.
    Huang M; Lopes GL; Insinga RP; Burke T; Ejzykowicz F; Zhang Y; Feliciano JL
    Immunotherapy; 2019 Dec; 11(17):1463-1478. PubMed ID: 31738117
    [No Abstract]   [Full Text] [Related]  

  • 20. A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
    Higashiyama RI; Yoshida T
    J Thorac Oncol; 2024 Sep; 19(9):e33-e34. PubMed ID: 39242142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.